PharmaResearch Launches Rejuran® at Aesthetics 2023 in Australia

Rejuran®, the flagship brand of Pharma Research (CEOs Thinkyou Kim and Ki-seok Kang), Is poised to make a significant entry into Australia, the largest aesthetics market in Oceania.

PharmaResearch unveiled Rejuran at Aesthetics 2023 hosted in Sydney, Australia from August 11 to 13, and presented the excellence and latest insights about its patented DNA Optimizing Technology (DOT™), a manufacturing method for PDRN and PN , with more than 500 local healthcare professionals.

Rejuran is the first polynucleotide (PN) product to be included on the Australian Register of Therapeutic Goods (ARTG) from the Therapeutic Goods Administration (TGA) in Australia.

An official from PharmaResearch said, "This marketing authorization for Rejuran is very meaningful as it is the first polynucleotide (PN) product approved in Australia. We expect Rejuran to grow as a leading product in the Australian aesthetics market, which was worth KRW 5 trillion as of last year."

Rejuran® is a medical device manufactured with polynucleotide (PN), a salmon-derived restorative substance, that applies PharmaResearch's patented DNA Optimizing Technology (DOT™) for the improvement of physical appearance.